- Previous Close
41.25 - Open
41.20 - Bid 41.45 x --
- Ask 41.50 x --
- Day's Range
40.95 - 42.00 - 52 Week Range
30.15 - 42.50 - Volume
29,175 - Avg. Volume
25,520 - Market Cap (intraday)
2.237B - Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
24.73 - EPS (TTM)
1.68 - Earnings Date Mar 28, 2025
- Forward Dividend & Yield 0.90 (2.18%)
- Ex-Dividend Date Jun 27, 2025
- 1y Target Est
48.49
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany. The company operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, Herpotherm, and epiivo brands. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE operates as a subsidiary of Themis Beteiligungs-AG.
ir.dermapharm.de3,497
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DMP.DE
View MorePerformance Overview: DMP.DE
Trailing total returns as of 3/19/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DMP.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DMP.DE
View MoreValuation Measures
Market Cap
2.25B
Enterprise Value
3.17B
Trailing P/E
24.55
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.92
Price/Book (mrq)
3.80
Enterprise Value/Revenue
2.73
Enterprise Value/EBITDA
10.61
Financial Highlights
Profitability and Income Statement
Profit Margin
7.72%
Return on Assets (ttm)
6.26%
Return on Equity (ttm)
15.75%
Revenue (ttm)
1.17B
Net Income Avi to Common (ttm)
90.58M
Diluted EPS (ttm)
1.68
Balance Sheet and Cash Flow
Total Cash (mrq)
118.57M
Total Debt/Equity (mrq)
174.10%
Levered Free Cash Flow (ttm)
120.61M